GlassScriptPhysician profile
Robert A Braastad
NPI 1487619573
$1,360.57
in general payments reported to CMS, 2019-2025
24 companies · $500 in 2025
The $500 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $134 · 2020: $78.45 · 2021: $51.59 · 2022: $101 · 2023: $294 · 2024: $202 · 2025: $500.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $996.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $996.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $235.02 | 2021-2024 | Watchman Access System, Avvigo Guidance System |
| Amgen INC. | $114.81 | 2023-2025 | Repatha, Repatha |
| Scpharmaceuticals INC. | $103.29 | 2025 | |
| Cvrx, INC. | $91.52 | 2025 | Barostim Neo System |
| Pfizer INC. | $89.84 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $74.15 | 2025 | |
| Medtronic, INC. | $73.83 | 2024-2025 | Closurefast, Linq II |
| Medtronic Vascular, INC. | $70.19 | 2019 | |
| Edwards Lifesciences Corporation | $63.37 | 2019 | |
| Cardiovascular Systems INC. | $50.73 | 2021-2022 | |
| Abbott Laboratories | $46.76 | 2025 | Thoratec Heartmate 3 Lvas Implant Kit, Esprit |
| Atricure, INC. | $46.21 | 2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $44.26 | 2022-2025 | Lifevest |
| Merck Sharp & Dohme LLC | $41.82 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.03 | 2022-2024 | Jardiance |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $32.36 | 2020-2021 | |
| Lexicon Pharmaceuticals, INC. | $25.01 | 2023 | Inpefa |
| Astrazeneca Pharmaceuticals LP | $19.18 | 2023 | Farxiga |
| Kiniksa Pharmaceuticals International, Plc | $18.33 | 2024 | Arcalyst |
| Alnylam Pharmaceuticals INC. | $17.25 | 2023 | Onpattro |
| Elutia, INC. | $16.91 | 2025 | Ecm Patch,Pouch |
| Esperion Therapeutics, INC. | $16.45 | 2024 | Nexletol |
| Cardiva Medical, INC. | $14.68 | 2025 | Cardiva Vascade Mvp Vvcs 6-12f |
| E.R. Squibb & Sons, L.L.C. | $13.57 | 2023 | Camzyos |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Braastad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.